Greifswald - CHEPLAPHARM is expanding its portfolio by acquiring the marketing rights for Rivotril from
'We were able to complete this very important project as a successful start to the new year. Rivotril perfectly complements our portfolio of benzodiazepines marketed worldwide. We are proud to be able to build on the long-standing business relationship with
Rivotril is a branded prescription drug that is used to treat epilepsy and panic disorder. This benzodiazepine with the active ingredient clonazepam is a well-established product that is marketed worldwide. Rivotril was introduced in 1973 and is currently approved in approximately 85 countries.
Contact:
Tel: +49 (0) 3834 3914-0
Fax: +49 (0) 3834 3914-119
Email: info (at)cheplapharm.com
(C) 2021 Electronic News Publishing, source